Purpose: Although rapid-acting insulins (RAIs) are used frequently in Korean clinical settings, evidence on their use is limited. This study explores the pattern and clinical effectiveness of the use of RAIs in Korean patients with type 2 diabetes mellitus (T2DM). Patients and Methods: This non-interventional, observational study enrolled patients (aged >18 years) with T2DM who were prescribed RAIs. The pattern of use and effectiveness of RAI analogs were evaluated over 6 months. Results: A total of 299/451 patients were analyzed. Approximately 90% (n/N=270/299) of the patients received insulin glulisine, which significantly reduced their levels of glycated hemoglobin (HbA1c: n=270, mean± standard deviation [SD]; −1.16±6.02%, p=0.0017), fasting plasma glucose (n=40; mean±SD: −54.9±90.89 mg/dl, p=0.0005), and post prandial blood glucose (n=35, mean±SD: −89.46± 105.68 mg/dl, p<0.0001) at 6 months, with a corresponding increase in body weight (BW) (n=197, mean±SD:1.45±3.64 kg, p<0.0001). At 6 months, more patients receiving an intensive regimen (basal insulin+≥2 RAI injections/day) had HbA1c <7% than those receiving a non-intensive regimen (basal insulin+1 RAI injection/day) (20.69% vs 7.46%; p=0.0333); the corresponding reduction in HbA1c was also higher in patients receiving the intensive regimen (p<0.0001). About one-fourth patients (n/N=22/95) were switched to the intensive regimen (from 1 to ≥2 RAI injections/day), and only 4.41% (n/N=9/204) of the patients were switched to 1 RAI injection/day. The patients receiving the intensive regimen showed higher levels of HbA1c reductions (mean±SD: −1.27±1.96%) compared with the maintenance group-1 RAI injection/day (mean±SD: −0.72±1.66%) (p=0.0459), without a significant increase in BW and body mass index. Conclusion: The insulin glulisine intensification regimen showed glycemic target achievement and can be considered a therapeutic tool in the management of T2DM patients.
|Number of pages||9|
|Journal||Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy|
|Publication status||Published - 2022|
Bibliographical noteFunding Information:
The authors would like to thank the study patients, their family, and caregivers who were involved in this study. Editorial support in the preparation of this publication was provided by Sonal More (Tata Consultancy Services Ltd., India) and paid for by Sanofi. Editorial support in the preparation of this publication was also provided by Anahita Gouri and Rohan Mitra of Sanofi, India. The authors, individually and collectively, are responsible for all content and editorial decisions and received no payment from Sanofi directly or indirectly (through a third party) related to the development/presentation of this publication. Funding The study was funded by Sanofi Aventis Korea Ltd.
The study was funded by Sanofi Aventis Korea Ltd.
© 2022 Kim et al.
All Science Journal Classification (ASJC) codes
- Internal Medicine